Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome

Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome - a Randomized Controlled Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02784457

Enrollment

Registered

2016-05-27

Start date

2014-06-30

Completion date

2016-03-31

Last updated

2016-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assisted Reproduction

Brief summary

Efficacy of the use of GnRH antagonist in treatment of those who develop early-onset severe ovarian hyperstimulation syndrome and had cancelled embryo transfer

Interventions

DRUGCetrorelix

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Women who develop early-onset severe ovarian hyperstimulation syndrome after controlled ovarian stimulation using long GnRH agonist protocol and hCG for triggering ovulation.

Exclusion criteria

* Women on short or antagonist protocols. * Women who received GnRH agonist for triggering ovulation. * Women who had embryo transfer.

Design outcomes

Primary

Measure	Time frame
Number of women who needed culdocentesis or paracentesis of the ascitic fluid	within 2 weeks of onset

Secondary

Measure	Time frame
Number of women who needed hospitalization	within 2 weeks of onset of symptoms
Time to regression of nausea/vomiting	within 2 weeks of onset of symptoms
Time to regression of large ovarian size	within 4 weeks of onset of symptoms

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026